EARLI
LIVE

Serial Number

97770271

Owner

Earli Inc.

Attorney

Connie Ellerbach

Filing Date

Jan 27, 2023

Add to watchlist:

No watchlists yet
View on USPTO

EARLI Trademark

Serial Number: 97770271

EARLI is a trademark filed by Earli Inc. on January 27, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). The application is currently pending registration.

Owner Contact Info

Earli Inc. (7 trademarks)

Mountain View, CA 94022

Entity Type: 03

Trademark Details

Filing Date

January 27, 2023

Registration Date

Not Registered

Published for Opposition

October 15, 2024

Goods & Services

Scientific apparatus in the nature of medical laboratory research instruments for the detection and localization of diseases, pathogens and toxins in a biological sample obtained from humans and animals for research use

Pharmaceutical and veterinary preparations and products for medical purposes for the prevention, detection, localization, and treatment of infectious viral-based, diseases, infectious bacterial-based diseases, infectious fungal-based diseases, autoimmune diseases, allergies, heart- and vascular-based diseases, cerebrovascular disease, neurological disorders and diseases, metabolic diseases, genetic diseases, blood-based diseases, kidney diseases, pancreatic diseases, muscular and neuromuscular diseases, gastrointestinal diseases and conditions, and toxins in the body tissue and fluids of humans and animals; Drug delivery agents in the form of tablet coatings, edible wafers, powders, tablets, and capsules that facilitate the delivery of other pharmaceutical preparations into human and animal bodies; Reagents for use in therapeutics for medical purposes; Diagnostic and therapeutic preparations for medical purposes, namely, diagnostic preparations and therapeutic pharmaceutical preparations for detecting and treating infectious viral-based diseases, infectious bacterial-based diseases, infectious fungal based diseases, autoimmune diseases, allergies, heart- and vascular-based diseases, cerebrovascular disease, neurological disorders and diseases, metabolic diseases, genetic diseases, blood-based diseases, kidney diseases, pancreatic diseases, muscular and neuromuscular diseases, and gastrointestinal diseases and conditions, and for detecting the presence of toxins in body tissue and fluids; medical diagnostic reagents and assays for testing of body fluids, reagents for medical use, diagnostic reagents for medical uses, enzymes for medical purposes, and diagnostic nucleotides for medical use; medical diagnostic assays for testing of body fluids, biological preparations in the nature of recombinant nucleic acid vectors, biological preparations in the nature of recombinant viral vectors, transfection agents being reagents for medical use, reagents for medical use, enzymes for medical purposes, and diagnostic nucleotides for medical purposes, and diagnostic nucleotides for medical use, all for the foregoing being for the treatment of infectious viral-based, diseases, infectious bacterial-based diseases, infectious fungal-based diseases, autoimmune diseases, allergies, heart- and vascular-based diseases, cerebrovascular disease, neurological disorders and diseases, metabolic diseases, genetic diseases, blood-based diseases, kidney diseases, pancreatic diseases, muscular and neuromuscular diseases, gastrointestinal diseases and conditions, and toxins in the body tissue and fluids of humans and animals; medical diagnostic assays and reagents for testing of body fluids, reagents for medical use, enzymes for medical purposes, and diagnostic nucleotides for medical use, all the forgoing for medical diagnostic and treatment purposes, namely, for use in detecting and treating infectious viral-based diseases, infectious bacterial-based diseases, infectious fungal-based diseases, autoimmune diseases, allergies, heart- and vascular-based diseases, cerebrovascular disease, neurological disorders and diseases, metabolic diseases, genetic diseases, blood-based diseases, kidney diseases, pancreatic diseases, muscular and neuromuscular diseases, and gastrointestinal diseases and conditions, and for use in detecting the presence of toxins in body tissue and fluids and for eliminating toxins from body tissue and fluids; therapeutic diagnostic agents for medical purposes, therapeutic agents in the nature of therapeutic pharmaceuticals for the treatment of cancer, infectious viral-based diseases, infectious bacterial-based diseases, infectious fungal-based diseases, autoimmune diseases, allergies, respiratory diseases, heart- and vascular-based diseases, cerebrovascular disease, neurological disorders and diseases, metabolic diseases, genetic diseases, blood-based diseases, kidney diseases, liver and pancreatic diseases, muscular and neuromuscular diseases, and gastrointestinal diseases and conditions, and therapeutic agents being therapeutic diagnostic and pharmaceutical preparations for detecting the presence of toxins in body tissue and fluid and for eliminating toxins from body tissue and fluids; therapeutic agents for medical diagnostic purposes and treatment purposes, namely, biological preparation in the nature of viral vectors and non-viral transfection agents being reagents for medical use based on linear or branched polyethyleneimines, nano-particles, lipophilic particles, peptides, micelles, dendrimers, hydrogels, synthetic or naturally derived exosomes, polymeric composition, or virus-like particles, that facilitate the delivery of a wide range of pharmaceuticals or nucleic acid sequences into human and animal bodies to detect and treat infectious viral-based diseases, infectious bacterial-based diseases, infectious fungal-based diseases, autoimmune diseases, allergies, heart- and vascular-based diseases, cerebrovascular disease, neurological disorders and diseases, metabolic diseases, genetic diseases, blood-based diseases, kidney diseases, pancreatic diseases, muscular and neuromuscular diseases, and gastrointestinal diseases and conditions, and for eliminating toxins in body tissue and fluids

Medical devices for delivering pharmaceutical preparations and genetic material into human or animal tissues and cells for the purpose of diagnosis of disease or treatment of disease, pathogens, and toxins in humans and animals, namely, syringes, implantable drug delivery pumps with and without catheters, infusion pumps, drug delivery catheters, infusion sets, cannulas, transdermal drug delivery patches, autoinjectors being injection devices for administering drugs, electroporators being electromagnetic drug delivery apparatus for medical use, and inhaled delivery devices being inhalers for medical purposes, all the forgoing sold empty and without medication; Medical devices for the delivery of pharmaceutical preparations and genetic material into human or animal tissues and cells for the purpose of diagnosis of disease or treatment of disease, pathogens, and toxins in humans and animals, namely, inhalers for medical purposes, sold empty and drug delivery patches sold without medication; Medical instruments for use in treating infectious diseases and for eliminating pathogens and toxins in humans and animals

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 26, 2025 EXRA
SOU EXTENSION 2 GRANTED
Oct 25, 2025 EX2G
SOU EXTENSION 2 FILED
Oct 25, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Oct 25, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 7, 2025 EXRA
SOU EXTENSION 1 GRANTED
Mar 7, 2025 EX1G
SOU EXTENSION 1 FILED
Mar 6, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 6, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 26, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 15, 2024 NPUB
PUBLISHED FOR OPPOSITION
Oct 15, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 25, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 6, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 14, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 14, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Aug 14, 2024 ERFR
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
May 3, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
May 3, 2024 XELR
NOTIFICATION OF FINAL REFUSAL EMAILED
Feb 16, 2024 GNFN
FINAL REFUSAL E-MAILED
Feb 16, 2024 GNFR
FINAL REFUSAL WRITTEN
Feb 16, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 19, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 18, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 18, 2024 TROA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Nov 2, 2023 GPRN
PRIORITY ACTION E-MAILED
Nov 2, 2023 GPRA
PRIORITY ACTION WRITTEN
Nov 2, 2023 CPRA
ASSIGNED TO EXAMINER
Oct 26, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 15, 2023 NWOS
NEW APPLICATION ENTERED
Jan 31, 2023 NWAP